Back to Search
Start Over
Supplementary Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplement (adjusted per last reviewer comment).
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....6ee191782a4e9799f5f8dbba012c1019